Reshma Kewalramani, Vertex CEO (Photo by Barry Chin/The Boston Globe via Getty Images)
In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia
Vertex and CRISPR Therapeutics have won the first-ever approval for a therapy created with CRISPR gene editing, as the UK drug regulator MHRA greenlights their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.